{"id":11964,"date":"2025-11-04T10:29:46","date_gmt":"2025-11-04T09:29:46","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=11964"},"modified":"2026-03-03T10:23:59","modified_gmt":"2026-03-03T09:23:59","slug":"serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/","title":{"rendered":"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration"},"content":{"rendered":"\n<p><strong><em>La population suisse est satisfaite de la qualit\u00e9 du syst\u00e8me de sant\u00e9, mais il y a nettement des obstacles \u00e0 l\u2019acc\u00e8s aux nouveaux m\u00e9dicaments. D\u00e9couvrez dans la deuxi\u00e8me partie de notre s\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 pourquoi les patient-e-s doivent attendre de plus en plus longtemps les traitements innovants et quelle est la position de la Suisse en comparaison internationale.<\/em><\/strong><\/p>\n\n\n\n<p>La population continue de trouver que la Suisse dispose d\u2019un excellent syst\u00e8me de sant\u00e9: 73% des personnes interrog\u00e9es \u00e9valuent sa qualit\u00e9 comme bonne ou tr\u00e8s bonne. Mais cette \u00e9valuation varie entre les diff\u00e9rentes r\u00e9gions linguistiques: tandis qu\u2019en Suisse al\u00e9manique (27%) et italophone (25%), environ un quart estiment que la qualit\u00e9 du syst\u00e8me de sant\u00e9 est tr\u00e8s bonne, 16% seulement sont de cet avis en Suisse romande. Au total, on y est majoritairement satisfait de la qualit\u00e9 du syst\u00e8me de sant\u00e9, mais moins r\u00e9solument que dans les autres r\u00e9gions linguistiques.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/interpharma.ch\/wp-content\/uploads\/2025\/11\/image-2.png\" alt=\"\" class=\"wp-image-31066\" style=\"width:772px;height:auto\"\/><\/figure>\n\n\n\n<p>La population suisse a aussi depuis des ann\u00e9es une opinion tr\u00e8s positive stable de l\u2019acc\u00e8s aux traitements. On le doit en partie \u00e0 une autorit\u00e9 d\u2019homologation des m\u00e9dicaments forte et ind\u00e9pendante, ce qui est dans l\u2019int\u00e9r\u00eat de la place pharmaceutiques suisse et de la s\u00e9curit\u00e9 des patient-e-s. Gr\u00e2ce \u00e0 de nouvelles proc\u00e9dures attrayantes, on peut observer en comparaison internationale avec d\u2019autres autorit\u00e9s une am\u00e9lioration substantielle de la dur\u00e9e de la proc\u00e9dure d\u2019autorisation de mise sur le march\u00e9 (AMM) en Suisse entre 2019 et 2021, comparable \u00e0 pr\u00e9sent avec celle de l\u2019autorit\u00e9 europ\u00e9enne d\u2019homologation EMA (European Medicines Agency).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-la-suisse-prend-du-retard\"><strong>La Suisse prend du retard<\/strong><\/h2>\n\n\n\n<p>Mais il faut aussi observer les dessous de l\u2019acc\u00e8s des patient-e-s: l\u2019octroi de l\u2019AMM par l\u2019autorit\u00e9 d\u2019homologation ne signifie pas que les patient-e-s aient tout de suite acc\u00e8s \u00e0 \u00e9galit\u00e9 au m\u00e9dicament, il faut d\u2019abord que la prise en charge par l\u2019assurance de base (AOS) soit fix\u00e9e. Et comme ce processus prend de plus en plus de temps, les patient-e-s attendent de plus en plus longtemps la prise en charge par les caisses-maladie d\u2019un m\u00e9dicament nouvellement autoris\u00e9 et donc sa disponibilit\u00e9 g\u00e9n\u00e9rale. C\u2019est l\u2019Office f\u00e9d\u00e9ral de la sant\u00e9 publique (OFSP) qui d\u00e9cide de l\u2019admission dans la liste des sp\u00e9cialit\u00e9s et donc de la disponibilit\u00e9 g\u00e9n\u00e9rale du m\u00e9dicament. En 2024, l\u2019attente entre l\u2019AMM et l\u2019admission dans la LS a \u00e9t\u00e9 de 189&nbsp;jours, alors que la l\u00e9gislation pr\u00e9voit un d\u00e9lai maximal de 60&nbsp;jours. La tendance \u00e0 long terme est clairement \u00e0 la hausse et l\u2019OFSP n\u2019a respect\u00e9 le d\u00e9lai l\u00e9gal de 60&nbsp;jours que dans 6% des cas. Ce sont les patient-e-s qui en souffrent, car nombre d\u2019entre eux et elles ne peuvent pas attendre si longtemps.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/interpharma.ch\/wp-content\/uploads\/2025\/11\/image-3.png\" alt=\"\" class=\"wp-image-31069\" style=\"width:840px;height:auto\"\/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rene-buholzer-directeur-d-interpharma-declare-a-ce-sujet\">Ren\u00e9 Buholzer, directeur d\u2019Interpharma, d\u00e9clare \u00e0 ce sujet:<\/h2>\n\n\n\n<p><em>\u00abNotre vision est un syst\u00e8me de sant\u00e9 de haute qualit\u00e9, qui mette les patientes et patients au centre des consid\u00e9rations. L\u2019industrie pharmaceutique pratiquant la recherche veut et peut \u00eatre jug\u00e9e \u00e0 l\u2019aune du b\u00e9n\u00e9fice que ses innovations leur apportent. Mais pour que ce b\u00e9n\u00e9fice puisse se d\u00e9ployer, il faut d\u2019urgence assurer la disponibilit\u00e9 des m\u00e9dicaments innovants d\u00e8s qu\u2019ils obtiennent l\u2019autorisation de mise sur le march\u00e9. Il n\u2019y a pas eu assez de progr\u00e8s en ce sens par le pass\u00e9, c\u2019est pourquoi Interpharma continue de s\u2019investir sans rel\u00e2che pour am\u00e9liorer cette situation\u00bb.<\/em><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Le Moniteur de la sant\u00e9 d\u2019Interpharma est une enqu\u00eate repr\u00e9sentative r\u00e9alis\u00e9e chaque ann\u00e9e par gfs.bern sur mandat d\u2019Interpharma. Entre le 3&nbsp;mars et le 25&nbsp;mars 2025, 1200 personnes disposant du droit de vote ont \u00e9t\u00e9 interrog\u00e9es dans toute la Suisse.<\/p>\n\n\n\n<p><a href=\"https:\/\/interpharma.ch\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-1-un-quart-de-siecle\/?lang=fr\">Cliquez ici pour acc\u00e9der \u00e0 la partie 1 de la s\u00e9rie d&rsquo;articles<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/interpharma.ch\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-3-la-perception-des-couts-et-les-faits-ne-concordent-pas-toujours\/?lang=fr\">Cliquez ici pour acc\u00e9der \u00e0 la partie 3 de la s\u00e9rie d\u2019articles<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La population suisse est satisfaite de la qualit\u00e9 du syst\u00e8me de sant\u00e9, mais il y a nettement des obstacles \u00e0 l\u2019acc\u00e8s aux nouveaux m\u00e9dicaments. D\u00e9couvrez dans la deuxi\u00e8me partie de notre s\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 pourquoi les patient-e-s doivent attendre de plus en plus longtemps les traitements innovants et [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3711,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[127,131],"class_list":["post-11964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-acces-des-patients","tag-politique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration\" \/>\n<meta property=\"og:description\" content=\"La population suisse est satisfaite de la qualit\u00e9 du syst\u00e8me de sant\u00e9, mais il y a nettement des obstacles \u00e0 l\u2019acc\u00e8s aux nouveaux m\u00e9dicaments. D\u00e9couvrez dans la deuxi\u00e8me partie de notre s\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 pourquoi les patient-e-s doivent attendre de plus en plus longtemps les traitements innovants et [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T09:29:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:23:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png\" \/>\n\t<meta property=\"og:image:width\" content=\"560\" \/>\n\t<meta property=\"og:image:height\" content=\"602\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration\",\"datePublished\":\"2025-11-04T09:29:46+00:00\",\"dateModified\":\"2026-03-03T09:23:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/\"},\"wordCount\":711,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png\",\"keywords\":[\"Acc\u00e8s des patients\",\"Politique\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/\",\"name\":\"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png\",\"datePublished\":\"2025-11-04T09:29:46+00:00\",\"dateModified\":\"2026-03-03T09:23:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png\",\"width\":560,\"height\":602},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/","og_locale":"fr_FR","og_type":"article","og_title":"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration","og_description":"La population suisse est satisfaite de la qualit\u00e9 du syst\u00e8me de sant\u00e9, mais il y a nettement des obstacles \u00e0 l\u2019acc\u00e8s aux nouveaux m\u00e9dicaments. D\u00e9couvrez dans la deuxi\u00e8me partie de notre s\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 pourquoi les patient-e-s doivent attendre de plus en plus longtemps les traitements innovants et [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/","og_site_name":"Interpharma","article_published_time":"2025-11-04T09:29:46+00:00","article_modified_time":"2026-03-03T09:23:59+00:00","og_image":[{"width":560,"height":602,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png","type":"image\/png"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration","datePublished":"2025-11-04T09:29:46+00:00","dateModified":"2026-03-03T09:23:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/"},"wordCount":711,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png","keywords":["Acc\u00e8s des patients","Politique"],"inLanguage":"fr-FR","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/","name":"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png","datePublished":"2025-11-04T09:29:46+00:00","dateModified":"2026-03-03T09:23:59+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2025\/11\/Screenshot-2025-11-03-090716.png","width":560,"height":602},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/serie-de-blogs-sur-le-moniteur-de-la-sante-2025-dinterpharma-partie-2-bonne-qualite-mais-potentiel-damelioration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"S\u00e9rie de blogs sur le Moniteur de la sant\u00e9 2025 d\u2019Interpharma, partie 2: Bonne qualit\u00e9 mais potentiel d\u2019am\u00e9lioration"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=11964"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11964\/revisions"}],"predecessor-version":[{"id":11965,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11964\/revisions\/11965"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/3711"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=11964"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=11964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}